{
    "data": [
        {
            "id": "4314301",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-27T13:21:52-05:00",
                "isLockedPro": false,
                "commentCount": 79,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences, Inc.: No Margin Of Safety",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "250517",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4314301-gilead-sciences-inc-no-margin-of-safety"
            }
        },
        {
            "id": "4313389",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-19T14:12:20-05:00",
                "isLockedPro": false,
                "commentCount": 234,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead Could Be A Strong Outperformer Over The Coming Years",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105409",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "248617",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4313389-why-gilead-be-strong-outperformer-over-coming-years"
            }
        },
        {
            "id": "4312644",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-16T03:54:08-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Reinforces Yescarta Commercial Product With Latest, Long-Term Survival Findings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "247838",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4312644-gilead-sciences-reinforces-yescarta-commercial-product-latest-long-term-survival-findings"
            }
        },
        {
            "id": "4299535",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-28T08:39:56-04:00",
                "isLockedPro": false,
                "commentCount": 97,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "As The Street Sours On Gilead, The Stock Looks Sweeter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "76898",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4299535-street-sours-on-gilead-stock-looks-sweeter"
            }
        },
        {
            "id": "4299464",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-27T21:59:50-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Soft, Yet Solid Enough",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "76796",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4299464-gilead-sciences-soft-yet-solid-enough"
            }
        },
        {
            "id": "4299154",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-25T13:02:26-04:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences' Turnaround Is Here",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "76587",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4299154-gilead-sciences-turnaround-is"
            }
        },
        {
            "id": "4298655",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-24T13:14:44-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Will Pull Levers Thursday",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "76364",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4298655-gilead-will-pull-levers-thursday"
            }
        },
        {
            "id": "4289185",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-02T12:47:41-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Deal With Galapagos NV Should Be A Winner",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "63896",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4289185-gilead-sciences-deal-galapagos-nv-should-be-winner"
            }
        },
        {
            "id": "4286468",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-18T13:34:56-04:00",
                "isLockedPro": false,
                "commentCount": 79,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Goodbye To Gilead As ViiV, Merck Besiege Its HIV Citadel",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "60871",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4286468-goodbye-to-gilead-viiv-merck-besiege-hiv-citadel"
            }
        },
        {
            "id": "4284856",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-12T12:08:50-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Future Of HCV Market Duopoly",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "59174",
                            "type": "sentiment"
                        },
                        {
                            "id": "59175",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4284856-future-of-hcv-market-duopoly"
            }
        },
        {
            "id": "4284784",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-12T09:20:49-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Chugs Along",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "59054",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4284784-gilead-chugs-along"
            }
        },
        {
            "id": "4280604",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-02T06:11:20-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: A Very Core Holding",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "56913",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4280604-gilead-sciences-core-holding"
            }
        },
        {
            "id": "4279844",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-31T18:46:49-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead At An Inflection Point: Examining The HIV Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55165",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4279844-gilead-inflection-point-examining-hiv-market"
            }
        },
        {
            "id": "4278915",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-30T08:59:38-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Earnings Preview",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55804",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4278915-gilead-earnings-preview"
            }
        },
        {
            "id": "4278515",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-29T00:42:50-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Through The Eyes Of A Dividend Growth Investor",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65393",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "55564",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4278515-gilead-through-eyes-of-dividend-growth-investor"
            }
        },
        {
            "id": "4275305",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-16T19:39:56-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Behind Gilead's Big Move On Galapagos",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "213267",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4275305-behind-gileads-big-move-on-galapagos"
            }
        },
        {
            "id": "4275289",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-16T17:19:30-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Recent Progress With Filgotinib Plus Latest Partnership Expansion Points To Gilead's New Solid Path",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "52490",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4275289-recent-progress-filgotinib-plus-latest-partnership-expansion-points-to-gileads-new-solid-path"
            }
        },
        {
            "id": "4273869",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-08T11:01:23-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead And The Status Of My Model Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104439",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "50108",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273869-gilead-and-status-of-model-portfolio"
            }
        },
        {
            "id": "4272847",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-30T17:40:00-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie And Gilead - 2 Different Strategies To Improve Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105284",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48605",
                            "type": "sentiment"
                        },
                        {
                            "id": "48606",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272847-abbvie-and-gilead-2-different-strategies-to-improve-growth"
            }
        },
        {
            "id": "4272565",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-27T19:26:00-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "5 Reasons Why You Should Be Interested In Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48531",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272565-5-reasons-why-you-should-be-interested-in-gilead-sciences"
            }
        },
        {
            "id": "4272120",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-26T00:26:48-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Latest Bolt-On Buys Point To A New Way Of Approaching Drug Development",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "47988",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4272120-gileads-latest-bolt-on-buys-point-to-new-way-of-approaching-drug-development"
            }
        },
        {
            "id": "4271854",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-24T14:20:23-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead And Cilofexor In Phase 3 Primary Sclerosing Cholangitis: Making Progress",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104202",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "47266",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4271854-gilead-and-cilofexor-in-phase-3-primary-sclerosing-cholangitis-making-progress"
            }
        },
        {
            "id": "4269731",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-11T17:29:35-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Hopes To Continue Sales Expansion Of Yescarta - Results From KTE-X19 Step In The Right Direction",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "44715",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4269731-gilead-hopes-to-continue-sales-expansion-of-yescarta-results-from-kte-x19-step-in-right"
            }
        },
        {
            "id": "4267656",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-31T15:52:18-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: The Next Shoe To Drop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "42071",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4267656-gilead-next-shoe-to-drop"
            }
        },
        {
            "id": "4265263",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-20T09:54:14-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Still A Good Pick Despite Risks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "39028",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4265263-gilead-sciences-still-good-pick-despite-risks"
            }
        },
        {
            "id": "4264267",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-15T12:01:34-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Is A Good Long-Term Investment Without A Moat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "38063",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4264267-gilead-sciences-is-good-long-term-investment-without-moat"
            }
        },
        {
            "id": "4263810",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-14T11:04:16-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Has Levers To Pull",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "37679",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4263810-gilead-levers-to-pull"
            }
        },
        {
            "id": "4262041",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-09T13:52:53-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences At The Filgotinib And Selonsertib Crossroads",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "36623",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4262041-gilead-sciences-filgotinib-and-selonsertib-crossroads"
            }
        },
        {
            "id": "4261699",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-08T18:56:08-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Earnings Might Point To A Potential Turnaround In Coming Year",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "36618",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4261699-gileads-earnings-might-point-to-potential-turnaround-in-coming-year"
            }
        },
        {
            "id": "4259526",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-03T08:04:35-04:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "O'Day: The Man Of The Hour For Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "35303",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4259526-oday-man-of-hour-for-gilead"
            }
        },
        {
            "id": "4257146",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-26T13:01:07-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24589",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "33634",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4257146-biotech-news-recap-gilead-sciences-stellar-data-falls-short"
            }
        },
        {
            "id": "4256398",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-24T15:57:09-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Isn't Satisfied With Only A Few NASH Deals, Presses On With More",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "32750",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4256398-gilead-sciences-isnt-satisfied-only-nash-deals-presses-on"
            }
        },
        {
            "id": "4255076",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-17T19:00:30-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Wants To Reignite Its NASH Portfolio With 2 Advancements",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "31855",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4255076-gilead-sciences-wants-to-reignite-nash-portfolio-2-advancements"
            }
        },
        {
            "id": "4254589",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-16T13:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead And The Pain Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "31146",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4254589-gilead-and-pain-ahead"
            }
        },
        {
            "id": "4254048",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-11T15:48:13-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Hitting Bottom",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "30169",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4254048-gilead-sciences-hitting-bottom"
            }
        },
        {
            "id": "4252482",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-02T21:10:31-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Has A Shot To Regain Investor Confidence With Inflammatory Disorder Drug Filgotinib",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "27999",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4252482-gilead-shot-to-regain-investor-confidence-inflammatory-disorder-drug-filgotinib"
            }
        },
        {
            "id": "4250764",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-25T07:28:29-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Will Provide Gilead The Growth Needed For Multiple Expansion?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "25889",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4250764-what-will-provide-gilead-growth-needed-for-multiple-expansion"
            }
        },
        {
            "id": "4242246",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-19T18:43:30-05:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Can Gilead Recover After Latest Earnings Downfall?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "8733",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4242246-can-gilead-recover-after-latest-earnings-downfall"
            }
        },
        {
            "id": "4241397",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-15T08:51:31-05:00",
                "isLockedPro": false,
                "commentCount": 156,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Mousetrap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104723",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "8168",
                            "type": "sentiment"
                        },
                        {
                            "id": "8169",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4241397-gileads-mousetrap"
            }
        },
        {
            "id": "4241259",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-14T18:30:01-05:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: What Just Happened?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "8272",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4241259-gilead-what-just-happened"
            }
        },
        {
            "id": "4241249",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-14T17:57:26-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Could Be The Winner From Washington State's Winner-Take-All Hep C Proposal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103071",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "8219",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4241249-gilead-be-winner-from-washington-states-winner-take-all-hep-c-proposal"
            }
        },
        {
            "id": "4240332",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-12T16:33:20-05:00",
                "isLockedPro": false,
                "commentCount": 85,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2 Dividend Blue-Chips Set To Soar And 1 You Should Ignore",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7968",
                            "type": "sentiment"
                        },
                        {
                            "id": "7969",
                            "type": "sentiment"
                        },
                        {
                            "id": "7970",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4240332-2-dividend-blue-chips-set-to-soar-and-1-you-should-ignore"
            }
        },
        {
            "id": "4239990",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-12T07:33:00-05:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Reaching An Inflection Point",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105057",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7605",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4239990-gilead-sciences-reaching-inflection-point"
            }
        },
        {
            "id": "4239466",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-08T12:47:17-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "After Humira: AbbVie's Upa Vs. Gilead's Filgo",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6783",
                            "type": "sentiment"
                        },
                        {
                            "id": "6784",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4239466-after-humira-abbvies-upa-vs-gileads-filgo"
            }
        },
        {
            "id": "4239164",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-07T16:09:11-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Gilead's Fourth Quarter Call Told Us About Their Core Business",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104999",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7312",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4239164-what-gileads-fourth-quarter-call-told-us-core-business"
            }
        },
        {
            "id": "4238879",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-07T04:58:25-05:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: What A Difference An O'Day Can Make",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7334",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4238879-gilead-what-difference-oday-can-make"
            }
        },
        {
            "id": "4238401",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-05T21:02:16-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Stable But Non-Inspiring",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7215",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4238401-gilead-sciences-stable-non-inspiring"
            }
        },
        {
            "id": "4235845",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-27T12:41:52-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead And Selonsertib In NASH Fibrosis And Compensated Cirrhosis: The FDA Guidelines For Conditional Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104202",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6056",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235845-gilead-and-selonsertib-in-nash-fibrosis-and-compensated-cirrhosis-fda-guidelines-for"
            }
        },
        {
            "id": "4235554",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-25T04:43:23-05:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Economics Of Cures - Gilead At A Turning Point",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5930",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4235554-economics-of-cures-gilead-turning-point"
            }
        },
        {
            "id": "4235433",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-24T17:10:07-05:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update On NASH Antifibrotics: Allergan, Gilead, Conatus, Galectin",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104723",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "5861",
                            "type": "sentiment"
                        },
                        {
                            "id": "5862",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4235433-update-on-nash-antifibrotics-allergan-gilead-conatus-galectin"
            }
        },
        {
            "id": "4233379",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-15T04:26:03-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Rowan Street Capital Q3'18 Letter: Exploiting The Market's Fear And Greed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67473",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "576527",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4233379-rowan-street-capital-q318-letter-exploiting-markets-fear-and-greed"
            }
        },
        {
            "id": "4233225",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-14T12:01:42-05:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is 2019 The Turnaround Year For Gilead Sciences?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103765",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4575",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4233225-is-2019-turnaround-year-for-gilead-sciences"
            }
        },
        {
            "id": "4232316",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-09T11:08:32-05:00",
                "isLockedPro": false,
                "commentCount": 108,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Is Gearing Release Of NASH Results Soon, But Other Deals Are Still Rolling In",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4265",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4232316-gilead-is-gearing-release-of-nash-results-soon-deals-are-still-rolling-in"
            }
        },
        {
            "id": "4231226",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-03T09:43:42-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Top Biotech Pick For The Next Decade With An Options Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3502",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231226-gilead-sciences-top-biotech-pick-for-next-decade-options-play"
            }
        }
    ]
}